title: [Study of matrine's use on the reversion of obtained multi-drug resistance of mice S80 tumour cell].
abstract: OBJECTIVE
  To Observe the effect caused by matrine's used on the reversion of obtained multi-drug resistance of mice S180's tumour cell induced by chemotherapy of Cisplatin + 5-FU + Cytoxan (PFC) and discuss its molecular mechanism.
  
  
  METHODS
  Patterned the methods of PFC chemotherapy in clinic, the mice were given Cisplatim 3 mg/kg x ip once a week and Cytoxan, CTX and 5-FU 3 mg/kg x ip once everyday for 4 weeks to set up the mice models of multi-drug resistance of S180 tumor cell. At the same time, gave the mice models matrine 4 weeks, and observed the P170, LRP, TOPO II by flow cytometry.
  
  
  RESULTS
  matrine could obviously reduce the express of P170, LRP and the activiation of TOPO II, correlated with mulit-drug resistance tumour cells which were induced by chemotherapy.
  
  
  CONCLUSIONS
  Matrine, with its adjustment of correlated biotic active matter, can intervene the ocurrence of the multidrug resistance of tumor cells induced by chemotherapy.
authors.affiliation: ShanDong Academy of Chinese Medicine, Jinan 250014, China.
authors.forename: Gui-Hai
authors.initials: GH
authors.lastname: Li
authors.forename: Mei
authors.initials: M
authors.lastname: Wang
authors.forename: Fu-Jun
authors.initials: FJ
authors.lastname: Sun
authors.forename: Xue-Rong
authors.initials: XR
authors.lastname: Wang
authors.forename: Xiao-Jing
authors.initials: XJ
authors.lastname: Li
authors.forename: Ge-Ping
authors.initials: GP
authors.lastname: Yin
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000235:genetics; D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis / Q000235:genetics; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D005434:Flow Cytometry; D005472:Fluorouracil / Q000008:administration & dosage; D051379:Mice; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D011807:Quinolizines / Q000008:administration & dosage / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000378:metabolism* / Q000473:pathology; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics / Q000378:metabolism; D000093842:Matrines; D000099187:Major Vault Protein
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D002945:Cisplatin; D003520:Cyclophosphamide; D004250:DNA Topoisomerases, Type II; D005472:Fluorouracil; D009363:Neoplasm Proteins; D011807:Quinolizines; D020394:Vault Ribonucleoprotein Particles; D000093842:Matrines; D000099187:Major Vault Protein